{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:07:25Z","timestamp":1791310045462,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001385","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000}}],"reference-count":374,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001385.pub2","type":"journal-article","created":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T19:23:19Z","timestamp":1170789799000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid"],"prefix":"10.1002","volume":"2014","author":[{"given":"E. Haydn","family":"Walters","sequence":"first","affiliation":[{"name":"School of Medicine, University of Tasmania; NHMRC CRE for Chronic Respiratory Disease; Hobart Tasmania Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Gibson","sequence":"additional","affiliation":[{"name":"John Hunter Hospital; Department of Respiratory and Sleep Medicine; Lookout Road New Lambton NSW Australia 2305"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby J","family":"Lasserson","sequence":"additional","affiliation":[{"name":"The Cochrane Collaboration; Cochrane Editorial Unit; 11-13 Cavendish Square London UK W1G 0AN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia AE","family":"Walters","sequence":"additional","affiliation":[{"name":"University of Tasmania; School of Medicine; MS1, 17 Liverpool Street PO Box 23 Hobart Tasmania Australia 7001"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0001|cit1","first-page":"278","article-title":"Salmeterol compared with current therapies in chronic asthma","volume":"47","author":"Adinoff","year":"1998","journal-title":"Journal of Family Practice"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1081-1206(10)62351-4","article-title":"A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler","volume":"86","author":"Bensch","year":"2001","journal-title":"Annals of Allergy Asthma & Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0003|cit3","first-page":"88","article-title":"QID Albuterol worsens peak flow variability in asthma whereas BID Formoterol does not [abstract]","volume":"80","author":"Della Cioppa","year":"1998","journal-title":"Annals of Allergy"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0004|cit4","unstructured":"FORNDA 20831_40 A twelve week, double-blind, parallel group trial comparing the safety, tolerability and efficacy of formoterol dry powder capsules for inhalation delivered by a single-dose inhaler versus albuterol metered dose inhaler device versus placebo in patients with mild to moderate asthma www.fda.gov 2001"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1378\/chest.124.1.70","article-title":"Serious asthma exacerbations in asthmatics treated with high-dose formoterol","volume":"124","author":"Mann","year":"2003","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1081-1206(10)61935-7","article-title":"One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma","volume":"89","author":"Bensch","year":"2002","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1378\/chest.124.1.70","article-title":"Serious asthma exacerbations in asthmatics treated with high-dose formoterol","volume":"124","author":"Mann","year":"2003","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD001385.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/thx.48.11.1121","article-title":"Changes in methacholine induced bronchoconstriction with the long acting beta2 agonist salmeterol in mild to moderate asthmatic patients","volume":"48","author":"Booth","year":"1993","journal-title":"Thorax"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0091-6749(97)70295-1","article-title":"A Twelve week comparison of salmeterol and salbutamol in the treatment of mild to moderate asthma- a Canadian multicentre study","volume":"99","author":"Boulet","year":"1997","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1183\/09031936.98.11051091","article-title":"Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction- influence of inhaled corticosteroids","volume":"11","author":"Boulet","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD001385.pub2-BIB0011|cit11","first-page":"1579","article-title":"Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma","volume":"4","author":"Busse","year":"1998","journal-title":"American Journal of Managed Care"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.clinthera.2004.10.004","article-title":"Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study","volume":"26","author":"Busse","year":"2004","journal-title":"Clnical Therapeutics"},{"issue":"17","key":"10.1002\/14651858.CD001385.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199210223271703","article-title":"Long term effects of a long acting beta adrenoceptor agonist in patients with mild asthma","volume":"327","author":"Cheung","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1378\/chest.119.5.1306","article-title":"A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients","volume":"119","author":"Cloosterman","year":"2001","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1046\/j.1365-2222.1999.00627.x","article-title":"Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids","volume":"29","author":"Cloosterman","year":"1999","journal-title":"Clinical & Experimental Allergy"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/rmed.2001.1243","article-title":"Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists","volume":"96","author":"Schayck","year":"2002","journal-title":"Respiratory Medicine"},{"issue":"2-4","key":"10.1002\/14651858.CD001385.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000024129","article-title":"Comparison of an inhaled corticosteroid (triamcinolone acetonide) to a long-acting bronchodilator (salmeterol), the combination, and placebo in mild-moderate adult asthmatic patients","volume":"118","author":"Creticos","year":"1999","journal-title":"International Archives of Allergy and Immunology"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0091-6749(96)80200-4","article-title":"Salmeterol does not cause tolerance during long term asthma therapy","volume":"98","author":"Arledge","year":"1996","journal-title":"Journal of Allergy & Clinical Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0020|cit19","first-page":"128","article-title":"Efficacy of inhaled salmeterol in the treatment of asthma","volume":"5","author":"D'Alonzo","year":"1995","journal-title":"European Respiratory Review"},{"issue":"18","key":"10.1002\/14651858.CD001385.pub2-BIB0019|cit20","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jama.1994.03510420044032","article-title":"Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma","volume":"271","author":"D'Alonzo","year":"1994","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0021|cit21","first-page":"243","article-title":"Safety of salmeterol in the maintenance treatment of asthma","volume":"75","author":"Nathan","year":"1995","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1183\/09031936.93.04101178","article-title":"Salmeterol-a 4 week study of a long acting beta2 adrenoceptor agonist for the treatment of reversible airways disease","volume":"4","author":"Dahl","year":"1991","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0023|cit23","first-page":"282","article-title":"Chronic dose-ranging studies with salmeterol","volume":"1","author":"Faurschou","year":"1991","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0024|cit24","first-page":"272","article-title":"Bronchoalveolar lavage studies","volume":"1","author":"Dahl","year":"1991","journal-title":"European Respiratory Review"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0954-6111(98)90352-3","article-title":"Low-dose formoterol Turbuhaler(TM) (Oxis(TM)) bid, a 3-month placebo-controlled comparison with terbutaline (qid)","volume":"92","author":"Ekstrom","year":"1998","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1081-1206(10)62816-5","article-title":"A 3 month comparison of formoterol with terbutaline via turbuhaler-A placebo controlled study","volume":"81","author":"Ekstrom","year":"1998","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0027|cit27","first-page":"176","article-title":"Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm","volume":"11","author":"Garcia","year":"2001","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00435255","article-title":"Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol and placebo in asthmatics","volume":"3","author":"Hyland","year":"1994","journal-title":"Quality of Life Research"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/thx.49.10.971","article-title":"Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care-UK Study Group","volume":"49","author":"Jones","year":"1994","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0030|cit30","first-page":"83","article-title":"A multicentre comparison of salmeterol and salbutamol on asthma-specific quality of life [abstract]","volume":"3","author":"Juniper","year":"1994","journal-title":"Quality of Life Research"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1164\/ajrccm.151.1.7812574","article-title":"Quality of life in asthma clinical trials-a comparison of salmeterol and salbutamol","volume":"151","author":"Juniper","year":"1995","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD001385.pub2-BIB0032|cit32","first-page":"A414","article-title":"The salmeterol xinafoate\/fluticasone propionate dry powder combination product via diskus(r) inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate dry powder alone","volume":"157","author":"Edwards","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1067\/mai.2000.105711","article-title":"Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma-A randomized, double-blind, placebo-controlled trial","volume":"105","author":"Kavuru","year":"2000","journal-title":"Journal of Allergy & Clinical Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0034|cit34","unstructured":"SFCA3002 A randomized, double-blind, parallel-group trial evaluating safety and efficacy of salmeterol 50mcg BID and fluticasone propionate 100mcg BID individually and in combination and placebo in subjects with asthma http:\/\/ctr.gsk.co.uk 2005"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0149-2918(98)80090-8","article-title":"Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients","volume":"20","author":"Kemp","year":"1998","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0036|cit36","first-page":"52","article-title":"Inhaled salmeterol powder compared with albuterol aerosol given regularly or as needed for asthma (abstract)","volume":"74","author":"Wolfe","year":"1995","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1378\/chest.115.3.642","article-title":"Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma-A randomized clinical trial","volume":"115","author":"Chervinsky","year":"1999","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0091-6749(99)70012-6","article-title":"A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine","volume":"104","author":"Kemp","year":"1999","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD001385.pub2-BIB0039|cit39","first-page":"323s","article-title":"Long term regular treatment with salmeterol is effective in protecting against bronchial hyperresponsiveness as measured by methacholine challenge in asthmatics","volume":"99","author":"Rosenthal","year":"1997","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1378\/chest.111.5.1249","article-title":"The effect of salmeterol on nocturnal symptoms, airway function and inflammation in asthma","volume":"111","author":"Kraft","year":"1997","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1081\/JAS-51334","article-title":"Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma","volume":"42","author":"LaForce","year":"2005","journal-title":"Journal of Asthma"},{"issue":"20","key":"10.1002\/14651858.CD001385.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1001\/jama.285.20.2583","article-title":"Long-acting \u00df2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial","volume":"285","author":"Lazarus","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/ajrccm.154.2.8756801","article-title":"A placebo controlled crossover comparison of salmeterol and salbutamol in patients with asthma","volume":"154","author":"Leblanc","year":"1996","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/pai.2005.18.25","article-title":"Safety and efficacy in children with persistent asthma treated with formoterol 10 mcg BID delivered via Certihaler: a novel multidose dry-powder inhaler","volume":"18","author":"Levy","year":"2005","journal-title":"Pediatric Asthma, Allergy, and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mai.2003.1500","article-title":"Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate","volume":"112","author":"Lindqvist","year":"2003","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1378\/chest.115.3.666","article-title":"Nocturnal Asthma. Effect of Salmeterol on Quality of Life and Clinical Outcomes","volume":"115","author":"Lockey","year":"1999","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/pai.1998.12.21","article-title":"Quality of life in pediatric asthma patients treated with salmeterol and impact on the daily activities of their parents","volume":"12","author":"Mahajan","year":"1998","journal-title":"Pediatric Asthma Allergy & Immunology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1081-1206(10)63159-6","article-title":"A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma","volume":"82","author":"Nathan","year":"1999","journal-title":"Annals of Allergy"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199807163390301","article-title":"Effect of long-term salmeterol treatment on exercise-induced asthma","volume":"339","author":"Nelson","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1164\/ajrccm.159.5.9807128","article-title":"Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma","volume":"159","author":"Nelson","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0051|cit51","unstructured":"SLGA5020 A single-center, randomized, double-blind, cross-over clinical trial to examine sub-sensitivity in adult subjects with asthma receiving salmeterol xinafoate 42mcg BID and placebo BID www.ctr.gsk.co.uk"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9343(94)90045-0","article-title":"Bronchodilator sub-sensitivity after chronic dosing with eformoterol in patients with asthma","volume":"97","author":"Newnham","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/thx.50.5.497","article-title":"Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients","volume":"50","author":"Newnham","year":"1995","journal-title":"Thorax"},{"issue":"9083","key":"10.1002\/14651858.CD001385.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(97)03211-X","article-title":"Association between beta2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics","volume":"350","author":"Tan","year":"1997","journal-title":"Lancet"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0091-6749(96)80200-4","article-title":"Salmeterol does not cause tolerance during long term asthma therapy","volume":"98","author":"Arledge","year":"1996","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0056|cit56","first-page":"243","article-title":"Safety of salmeterol in the maintenance treatment of asthma","volume":"75","author":"Nathan","year":"1995","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0059|cit57","first-page":"180","article-title":"Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy","volume":"75","author":"Pearlman","year":"1995","journal-title":"Annals of Allergy Asthma & Immunology"},{"issue":"20","key":"10.1002\/14651858.CD001385.pub2-BIB0057|cit58","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1056\/NEJM199211123272004","article-title":"A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma","volume":"327","author":"Pearlman","year":"1992","journal-title":"New England Journal Of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD001385.pub2-BIB0058|cit59","first-page":"301","article-title":"Controlling asthma symptoms: Salmeterol compared with salbutamol in large-scale multicentre studies","volume":"4","author":"Pearlman","year":"1994","journal-title":"European Respiratory Review"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1081-1206(10)62606-3","article-title":"Inhaled salmeterol and fluticasone: A study comparing monotherapy and combination therapy in asthma","volume":"82","author":"Pearlman","year":"1999","journal-title":"Annals of Allergy"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0061|cit61","unstructured":"FORNDA 20831_41 A twelve week, double-blind, parallel group trial comparing the safety, tolerability and efficacy of formoterol dry powder capsules for inhalation delivered by a single-dose inhaler versus albuterol metered dose inhaler device versus placebo in patients with mild to moderate asthma www.fda.gov 2001"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1378\/chest.124.1.70","article-title":"Serious asthma exacerbations in asthmatics treated with high-dose formoterol","volume":"124","author":"Mann","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1081\/JAS-120018780","article-title":"Formoterol Delivered via the Dry Powder Aerolizer\u00ae Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial","volume":"40","author":"Pleskow","year":"2003","journal-title":"Journal of Asthma"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1378\/chest.122.3.798","article-title":"Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects","volume":"122","author":"Prieto","year":"2002","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000236822","article-title":"Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels","volume":"105","author":"Ramage","year":"1994","journal-title":"International Archives of Allergy & Immunology"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0954-6111(94)90042-6","article-title":"Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol","volume":"88","author":"Ramage","year":"1994","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0067|cit67","first-page":"230P","article-title":"Effects of a six week course of salmeterol on bronchial reactivity","volume":"47","author":"Roberts","year":"1992","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1034\/j.1399-3003.1999.14b07.x","article-title":"The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma","volume":"14","author":"Roberts","year":"1999","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1378\/chest.116.3.595","article-title":"Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness","volume":"116","author":"Rosenthal","year":"1999","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0070|cit70","unstructured":"SAS30003 A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the salmeterol\/fluticasone propionate combination in HFA 134a MDI, 42\/88mcg BID, and salmeterol in propellant 11\/12 MDI, 42mcg BID, fluticasone propionate in propellant 11\/12 MDI, 88mcg BID, and placebo propellant HFA 134a MDI in adult and adolescent subjects with asthma www.ctr.gsk.co.uk"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0071|cit71","first-page":"S246","article-title":"Salmeterol\/fluticasone propionate combination via HFA MDI improves quality of life","volume":"107","author":"Edin","year":"2001","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0072|cit72","first-page":"A863","article-title":"Cardiovascular and hypothalamic-pituitary-adrenal axis safety of fluticasone propionate\/salmeterol HFA MDI in adolescent and adult patients with asthma","volume":"163","author":"Nathan","year":"2001","journal-title":"American Journal for Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0073|cit73","first-page":"A865","article-title":"Fluticasone propionate\/salmeterol HFA MDI has a rapid onset of effect in asthmatics treated with short or long-acting beta-agonists (BA) or inhaled corticosteroids (ICS)","volume":"163","author":"Pearlman","year":"2001","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0074|cit74","first-page":"100s","article-title":"The fluticasone propionate\/salmeterol HFA MDI is significantly more efficacious in treating asthma than placebo HFA MDI, fluticasone propionate CFC MDI or salmeterol CFC MDI","volume":"107","author":"Rooklin","year":"2001","journal-title":"Journal of Allergy and Clinicial Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0075|cit75","unstructured":"SAS30004 A randomized, double-blind, placebo-controlled, parallel-group 12-week trial evaluating the safety and efficacy of the salmeterol\/fluticasone propionate combination in GR106642X MDI, 50\/250mcg BID, and salmeterol in propellant 11\/12 MDI, 50mcg BID, fluticasone propionate in propellant 11\/12 MDI, 250mcg BID, and placebo propellant GR106642X MDI in adult and adolescent subjects with asthma www.ctr.gsk.co.uk 2004"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1183\/09031936.96.09081678","article-title":"A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients","volume":"9","author":"Schreurs","year":"1996","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0077|cit77","first-page":"A890","article-title":"Fluticasone propionate\/salmeterol delivered from a single inhaler demonstrates synergistic benefits in asthma","volume":"167","author":"Aggarwal","year":"2003","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/09031936.02.00294702","article-title":"Achieving guideline-based asthma control - does the patient benefit?","volume":"20","author":"Bateman","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0079|cit79","first-page":"A44","article-title":"Guideline-based asthma control reduces maximally the impact of upon patient-assessed quality of life","volume":"165","author":"Bateman","year":"2002","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0080|cit80","first-page":"98","article-title":"Concurrent use of salmeterol\/fluticasone propionate Diskus powder combination product and fluticasone propionate aqueous nasal spray does not adversely affect HPA-axis function","volume":"86","author":"Cook","year":"2001","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001385.pub2-BIB0081|cit81","first-page":"A195","article-title":"Asthma control with salmeterol\/fluticasone propionate (50\/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma","volume":"161","author":"Dorinsky","year":"2000","journal-title":"Journal Allergy & Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0082|cit82","first-page":"A112","article-title":"Improved ability to perform strenuous activities after treatment with fluticasone\/salmeterol combination","volume":"165","author":"Edin","year":"2002","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD001385.pub2-BIB0083|cit83","first-page":"S132","article-title":"The salmeterol\/fluticasone propionate (50\/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma","volume":"103","author":"Lumry","year":"1999","journal-title":"Journal Allergy & Clinical Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001385.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-199916002-00001","article-title":"Cost-effectiveness analyses of salmeterol\/fluticasone propionate combination product and fluticasone propionate in patients with asthma 1: Introduction and Overview","volume":"16","author":"Lundback","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00019053-200018060-00006","article-title":"Inhaled salmeterol\/fluticasone propionate combination: A pharmacoeconomic review of its use in the management of asthma","volume":"18","author":"Markham","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001385.pub2-BIB0086|cit86","first-page":"64","article-title":"Quality of life and asthma control assessment in patients previously treated with inhaled corticosteroids (ICS), treated with salmeterol\/fluticasone combination (SFC) metered dose inhaler (MDI)","volume":"56","author":"McCarthy","year":"2001","journal-title":"Thorax"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD001385.pub2-BIB0087|cit87","first-page":"47s","article-title":"Low dose salmeterol\/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids","volume":"20","author":"McCarthy","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1081\/JAS-120023573","article-title":"Improved ability to perform strenuous exercises after treatment with fluticasone\/salmeterol combination in patients with persistent asthma","volume":"40","author":"Nathan","year":"2003","journal-title":"Journal of Asthma"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001385.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00019053-199916002-00004","article-title":"Cost-effectiveness analysis of salmeterol\/fluticasone propionate 50\/250mcg vs fluticasone propionate 250mcg in adults and adolescents with asthma. 4: Results","volume":"16","author":"Palmqvist","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001385.pub2-BIB0090|cit90","first-page":"A196","article-title":"Salmeterol 50mcg\/fluticasone propionate 250mcg diskus combination product demonstrates improvements in lung function regardless of baseline corticosteroid therapy","volume":"161","author":"Pearlman","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001385.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00019053-199916002-00002","article-title":"Cost-effectiveness analyses of salmeterol\/fluticasone propionate combination product and fluticasone propionate in patients with asthma 2: Study Methodlogies","volume":"16","author":"Pieters","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD001385.pub2-BIB0092|cit92","first-page":"35s","article-title":"Salmeterol\/fluticasone propionate combination product improves quality of life in asthma patients","volume":"12","author":"Reese","year":"1998","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0093|cit93","unstructured":"SFCA3003 A randomized, double-blind, parallel-group trial evaluating safety and efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID individually and in combination and placebo in subjects with asthma http:\/\/ctr.gsk.co.uk 2005"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/ajrccm.161.2.9905091","article-title":"Combined salmeterol 50 mug and fluticasone propionate 250 in the diskus device for the treatment of asthma","volume":"161","author":"Shapiro","year":"2000","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001385.pub2-BIB0095|cit95","first-page":"U6","article-title":"Salmeterol\/fluticasone combination product in asthma - An evaluation of its cost-effectiveness vs fluticasone - foreword","volume":"16","author":"Stempel","year":"1999","journal-title":"Pharmacoeconmics"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0096|cit96","first-page":"A635","article-title":"The salmeterol xinafoate\/fluticasone propionate dry powder combination product via diskus r inhaler improves asthma control compared to the individual products in patients previously treated with inhaled corticosteroids","volume":"159","author":"White","year":"1999","journal-title":"American Journal of Respiratory and Critical Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Malozowski S Stadel BV Pian LP Comparison of beclomethasone, salmeterol, and placebo in children with asthma New England Journal of Medicine 1998 704 5","DOI":"10.1056\/NEJM199809033391014"},{"issue":"23","key":"10.1002\/14651858.CD001385.pub2-BIB0099|cit98","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM199712043372304","article-title":"A comparison of Beclomethasone, salmeterol and placebo in children with asthma","volume":"337","author":"Simons","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0098|cit99","first-page":"S402","article-title":"A one year placebo controlled study of the efficacy and safety of beclomethasone DP versus salmeterol in glucocorticoid naive children with asthma","volume":"99","author":"Simons","year":"1997","journal-title":"Journal of Allergy & Clinical Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0100|cit100","unstructured":"SLGA2004 A randomized, double-blind, double-dummy, placebo-controlled, comparative clinical trial of salmeterol xinafoate via multi-dose powder inhaler versus salmeterol xinafoate via Diskhaler for four weeks in adolescent and adult subjects with mild-to-moderate asthma. http:\/\/ctr.gsk.co.uk 2006"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0101|cit101","unstructured":"SLGA3014 www.fda.gov 2001"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0102|cit102","unstructured":"SLGL82 A double-blind parallel group study of inhaled salmeterol in asthmatic patients www.ctr.gsk.co.uk 2006"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0103|cit103","unstructured":"SLMP03 A single centre, randomised, double-blind, parallel group, placebo controlled study, to evaluate the effect of inhaled salmeterol xinafoate (50micrograms bd from a Diskhaler) on variations in bronchoconstriction induced by methacholine, in paediatric patients with mild to moderate asthma www.ctr.gsk.co.uk 2006"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"335s","DOI":"10.1378\/chest.124.4_MeetingAbstracts.335S","article-title":"Salmeterol Multicentre Asthma Research Trial (SMART): Results from an interim analysis","volume":"124","author":"Knobil","year":"2003","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1378\/chest.129.1.15","article-title":"The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol","volume":"129","author":"Nelson","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0106|cit106","article-title":"SMART: a double-blind, randomized, placebo-controlled surveillance study of asthma event outcomes in subjects receiving either usual pharmacotherapy of asthma or usual pharmacotherapy plus salmeterol 42mcg twice daily","author":"SLGA5011","year":"2006","journal-title":"http:\/\/www.ctr.gsk.co.uk"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0107|cit107","unstructured":"SMS40221 Comparing the efficacy and safety of inhaled salmeterol 50mcg BID and placebo via diskus in patients with reversible airways obstruction www.ctr.gsk.co.uk 2005"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ageing\/25.1.67","article-title":"The efficacy and safety of inhaled salmeterol 50 microg bd in older patients with reversible airflow obstruction","volume":"25","author":"Starke","year":"1996","journal-title":"Age & Ageing"},{"issue":"49","key":"10.1002\/14651858.CD001385.pub2-BIB0110|cit109","first-page":"7092","article-title":"Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone","volume":"158","author":"Steffensen","year":"1996","journal-title":"Ugeskrift for Laeger"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0109|cit110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.1995.tb02582.x","article-title":"Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol","volume":"50","author":"Steffensen","year":"1995","journal-title":"Allergy"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1081-1206(10)61913-8","article-title":"A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children","volume":"89","author":"Stelmach","year":"2002","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0112|cit112","first-page":"16","article-title":"Continuous eformoterol and beta 2-receptor responsiveness","volume":"81 Suppl","author":"Sussman","year":"1995","journal-title":"British Journal of Clinical Practice"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thorax.55.9.762","article-title":"Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism","volume":"55","author":"Taylor","year":"2000","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/thx.53.9.744","article-title":"Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol","volume":"53","author":"Taylor","year":"1998","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0954-6111(98)90112-3","article-title":"A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children","volume":"92","author":"Berg","year":"1998","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0116|cit116","first-page":"A76","article-title":"Regular salbutamol xinafoate compared with salbutamol as required in children with moderate asthma","volume":"4","author":"Berg","year":"1996","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1742-1241.2003.tb10629.x","article-title":"Efficacy and tolerability of formoterol Turbuhaler in children","volume":"57","author":"Berg","year":"2003","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1164\/ajrccm.159.1.9801007","article-title":"The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma","volume":"159","author":"Wallin","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0119|cit119","first-page":"A76","article-title":"Inhaled salmeterol powder compared with placebo administered over 12 weeks to children with mild to moderate asthma","volume":"153","author":"Pearlman","year":"1996","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0120|cit120","unstructured":"SLD390 www.fda.gov 2001"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1081-1206(10)63109-2","article-title":"Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma","volume":"81","author":"Weinstein","year":"1998","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0122|cit122","unstructured":"SLGA3010 A randomized, double-blind, double-dummy, comparative clinical trial of salmeterol 50mcg via the Diskus and salmeterol 50mcg via the metered-dose inhaler versus placebo for 12 weeks in adolescent and adult subjects with mild-to-moderate asthma www.ctr.gsk.co.uk"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1081-1206(10)62783-4","article-title":"Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma","volume":"84","author":"Wolfe","year":"2000","journal-title":"Annals of Allergy"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0124|cit124","unstructured":"SLGA3011 A randomized, double-blind, double-dummy, comparative clinical trial of salmeterol 50mcg via the Diskus and salmeterol 50mcg via the metered-dose inhaler versus placebo for twelve weeks in adolescent and adult subjects with mild-to-moderate asthma. www.ctr.gsk.co.uk"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1081-1206(10)62783-4","article-title":"Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma","volume":"84","author":"Wolfe","year":"2000","journal-title":"Annals of Allergy"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0126|cit126","unstructured":"FOR258D2307 www.fda.gov 2004"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD001385.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.jaci.2004.12.610","article-title":"Formoterol 24 mcg provides effective bronchodilation and is well tolerated in patients with persistent stable asthma [Abstract]","volume":"115","author":"Lapidus","year":"2005","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1378\/chest.129.1.27","article-title":"Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo","volume":"129","author":"Wolfe","year":"2006","journal-title":"Chest"},{"issue":"3-4","key":"10.1002\/14651858.CD001385.pub2-BIB0129|cit129","first-page":"193","article-title":"Treatment with salmeterol and quality of life in patients with asthma","volume":"66","author":"Wronska","year":"1998","journal-title":"Pneumonologia i Alergologia Polska"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0130|cit130","first-page":"517s","article-title":"The efficacy and safety of inhaled salmeterol (50mcg bd) compared with salbutamol (200mcg prn) in children with asthma","volume":"8 Suppl 19","author":"Gotz","year":"1995","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0131|cit131","unstructured":"SMS30013 A multicentre, randomised, double-blind, crossover study to investigate the efficacy and safety of inhaled salmeterol xinafoate (50\u00b5g twice daily from the Diskhaler) compared with placebo (from the Diskhaler) with salbutamol (200\u00b5g to use \u2018as required\u2019 from the Diskhaler) in children with asthma. www.ctr.gsk.co.uk"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00044011-199815030-00001","article-title":"Effect of long-term regular salmeterol treatment in children with moderate asthma","volume":"15","author":"Zarkovic","year":"1998","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/adc.81.1.45","article-title":"Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: A randomised controlled trial","volume":"81","author":"Akpinarli","year":"1999","journal-title":"Archives of Disease in Childhood"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1183\/09031936.93.02040325","article-title":"Formoterol, a new long acting bronchodilator for inhalation","volume":"2","author":"Arvidsson","year":"1989","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1183\/09031936.93.04101168","article-title":"Inhaled formoterol during one year in asthma: a comparison with salbutamol","volume":"4","author":"Arvidsson","year":"1991","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0091-6749(98)70245-3","article-title":"Beta 2-adrenceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma","volume":"101","author":"Aziz","year":"1998","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1183\/09031936.98.12030580","article-title":"Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol","volume":"12","author":"Aziz","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.115.3.623","article-title":"A bolus of inhaled budesonide rapidly reverses airway sub-sensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol","volume":"115","author":"Aziz","year":"1999","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1442-200X.1998.tb01921.x","article-title":"Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma","volume":"40","author":"Baki","year":"1998","journal-title":"Acta Paediatrica Japan"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0140|cit140","first-page":"1","article-title":"Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol\/fluticasone propionate (50\/250 microg) combination product (SAS 40023)","volume":"7","author":"Baumgarten","year":"2002","journal-title":"European Journal of Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/pulp.1993.1020","article-title":"Effect on airway responsiveness of six weeks treatment with salmeterol","volume":"6","author":"Beach","year":"1993","journal-title":"Pulmonary Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0091-6749(89)90385-0","article-title":"Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma","volume":"84","author":"Becker","year":"1989","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0143|cit143","first-page":"18","article-title":"Formoterol, a new beta2 agonist, improves chronic airway hyperresponsiveness in children with asthma","volume":"14","author":"Becker","year":"1993","journal-title":"Immunology and Allergy practice"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1378\/chest.108.5.1235","article-title":"Rapid onset of tolerance to the bronchoprotective effect of salmeterol","volume":"108","author":"Bhagat","year":"1995","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0145|cit145","first-page":"248","article-title":"Salmeterol for treatment of reversible obstructive airways disease in children","volume":"93","author":"Bishop","year":"1994","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1081-1206(10)62598-7","article-title":"Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol","volume":"82","author":"Blake","year":"1999","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0147|cit147","first-page":"318s","article-title":"Salmeterol: long term studies in children","volume":"5","author":"Boner","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD001385.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/thx.51.11.1100","article-title":"Salmeterol tachyphylaxis in steroid treated asthmatic subjects","volume":"51","author":"Booth","year":"1996","journal-title":"Thorax"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1183\/09031936.98.11051091","article-title":"Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction- influence of inhaled corticosteroids","volume":"11","author":"Boulet","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2222.2001.01014.x","article-title":"Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma","volume":"31","author":"Boulet","year":"2001","journal-title":"Clinical & Experimental Allergy"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0091-6749(97)70295-1","article-title":"A twelve- week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicentre study","volume":"99","author":"Boulet","year":"1997","journal-title":"Journal of Allergy & Clinical Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0152|cit152","first-page":"110","article-title":"The impact of salmeterol on asthma specific quality of life in patients reporting nocturnal asthma awakenings due to asthma","volume":"78","author":"Bowers","year":"1997","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1183\/09031936.95.08091494","article-title":"Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy- UK Study Group","volume":"8","author":"Boyd","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1398-9995.1994.tb00834.x","article-title":"Salmeterol compared with slow release terbutaline in nocturnal asthma: a multi center randomised double blind double dummy sequential clinical trial","volume":"49","author":"Brambilla","year":"1994","journal-title":"Allergy"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0149-2918(03)80202-3","article-title":"Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study","volume":"25","author":"Brambilla","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1183\/09031936.93.05091062","article-title":"A twelve month comparison of salmeterol with salbutamol in asthmatic patients","volume":"5","author":"Britton","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0157|cit157","first-page":"A408","article-title":"A Comparison of salmeterol 50mcg bd and 100mcg bd with salbutamol 200mcg qds in paediatric asthma","volume":"153","author":"Byrnes","year":"1996","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/thorax.55.9.780","article-title":"Salmeterol in paediatric asthma","volume":"55","author":"Byrnes","year":"2000","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0954-6111(99)90019-7","article-title":"A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics","volume":"93","author":"Campbell","year":"1999","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0160|cit160","first-page":"49","article-title":"The cost effectiveness of eformoterol via Turbohaler(TM) and salmeterol via pressurised metered dose inhaler and metered dose powder inhaler in mild to moderate asthma","volume":"3","author":"Campbell","year":"2000","journal-title":"Journal of Medical Economics"},{"issue":"11","key":"10.1002\/14651858.CD001385.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1183\/09031936.95.08111852","article-title":"Overnight protection by inhaled salmeterol on exercise-induced asthma in children","volume":"8","author":"Carlsen","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"6884","key":"10.1002\/14651858.CD001385.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/bmj.306.6884.1034","article-title":"Serevent nationwide surveillance study:comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment","volume":"306","author":"Castle","year":"1993","journal-title":"British Medical Journal"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD001385.pub2-BIB0163|cit163","first-page":"230","article-title":"Quality of life in moderate chronic asthma: salmeterol versus current treatments","volume":"47","author":"Charpin","year":"1992","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000064022","article-title":"A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia","volume":"69","author":"Chuchalin","year":"2002","journal-title":"Respiration"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1742-1241.2002.tb11182.x","article-title":"The safety and efficacy of formoterol (Oxis) turbuhaler plus budesonide (Pulmicort) turbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia","volume":"56","author":"Chuchalin","year":"2002","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0954-6111(93)90098-K","article-title":"Respiratory arrests in young asthmatics on salmeterol","volume":"87","author":"Clark","year":"1993","journal-title":"Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0167|cit167","first-page":"265","article-title":"Use of formoterol dry powder administered for three months via a single dose inhaler in 1,380 asthmatic patients","volume":"8","author":"Clauzel","year":"1998","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1155\/1997\/197209","article-title":"Salmeterol and airway response to allergen","volume":"4","author":"Cockcroft","year":"1997","journal-title":"Canadian Respiratory Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0091-6749(96)80511-2","article-title":"Asthma specific quality of life in patients treated with salmeterol or albuterol","volume":"97","author":"Cox","year":"1996","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.119.3.714","article-title":"Effectiveness and safety of salmeterol in non-specialist practice settings","volume":"119","author":"D'Urzo","year":"2001","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0171|cit171","unstructured":"D5125C00344 A 3-month, multi-centre, double-blind, double-dummy, randomised, parallel group, phase III study to investigate the efficacy and safety of formoterol HFA pMDI compared with placebo and Oxis Turbuhaler in subjects with asthma www.astrazeneca.com 2005"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0172|cit172","first-page":"N118","article-title":"Change of quality of life induced by salmeterol and salbutamol in adult asthmatic patients","volume":"50 Suppl","author":"Carli","year":"1995","journal-title":"Therapie"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/S0104-42301998000300002","article-title":"Efficacy of and tolerance to salmeterol compared to salbutamol in patients with bronchial asthma","volume":"44","author":"Oliveira","year":"1998","journal-title":"Revista da Associacao Medica Brasileira"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0091-6749(92)90435-5","article-title":"The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours","volume":"89","author":"Derom","year":"1992","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2222.1995.tb00397.x","article-title":"Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics","volume":"25","author":"Di-Lorenzo","year":"1995","journal-title":"Clinical & Experimental Allergy"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0176|cit176","first-page":"266","article-title":"Results of 30 days and 12 months treatment with salmeterol in patients with asthma and COPD","volume":"6","author":"Droszcz","year":"1999","journal-title":"Polski Merkuriusz Lekarski"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0177|cit177","first-page":"317","article-title":"Salmeterol and Salbutamol: long term efficacy and safety","volume":"5","author":"Faurschou","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"827-32","key":"10.1002\/14651858.CD001385.pub2-BIB0178|cit178","article-title":"Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies","volume":"10","author":"Faurschou","year":"1994","journal-title":"Allergy"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1183\/09031936.96.09091885","article-title":"Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids","volume":"9","author":"Faurschou","year":"1996","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0180|cit180","first-page":"243s","article-title":"Comparison of the anti-inflammatory effects of fluticasone and salmeterol in asthma- A placebo controlled, DB CO with bronchoscopy, bronchial methacholine provocation and lavage [abstract]","volume":"10","author":"Faurschou","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"31","key":"10.1002\/14651858.CD001385.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0091-6749(99)70467-7","article-title":"Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity","volume":"103","author":"FitzGerald","year":"1999","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"6765","key":"10.1002\/14651858.CD001385.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/bmj.301.6765.1365","article-title":"Salmeterol in nocturnal asthma-a double blind , placebo controlled trial of a long acting inhaled beta agonist","volume":"301","author":"Fitzpatrick","year":"1990","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/(SICI)1099-0496(199805)25:5<314::AID-PPUL5>3.0.CO;2-I","article-title":"Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma","volume":"25","author":"Fuglsang","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"6892","key":"10.1002\/14651858.CD001385.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/bmj.306.6892.1611","article-title":"Bronchodilator treatment in asthma","volume":"306","author":"Fuller","year":"1993","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1164\/ajrccm.150.4.7921429","article-title":"Effect of eight weeks treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics","volume":"150","author":"Gardiner","year":"1994","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0186|cit186","first-page":"A39","article-title":"Tolerance to salbutamol in allergen induced bronchoconstriction","volume":"151","author":"Giannini","year":"1995","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1378\/chest.115.3.629","article-title":"Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge","volume":"115","author":"Giannini","year":"1999","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1378\/chest.110.5.1229","article-title":"Effect of inhaled salmeterol on sulphur dioxide induced bronchoconstriction in asthmatic subjects","volume":"110","author":"Gong","year":"1996","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0189|cit189","first-page":"256","article-title":"The impact of salmeterol versus albuterol on disease specific quality of life in mild to moderate asthmatics","volume":"97","author":"Goodwin","year":"1996","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/adc.67.8.1014","article-title":"Prevention of exercise induced asthma by inhaled salmeterol xinafoate","volume":"67","author":"Green","year":"1992","journal-title":"Archives of Disease in Childhood"},{"issue":"8917","key":"10.1002\/14651858.CD001385.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(94)92996-3","article-title":"Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid","volume":"344","author":"Greening","year":"1994","journal-title":"Lancet"},{"issue":"8969","key":"10.1002\/14651858.CD001385.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(95)91265-7","article-title":"Bronchodilator sub-sensitivity to salbutamol after twice daily salmeterol in asthmatic patients","volume":"346","author":"Grove","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/thx.51.6.585","article-title":"Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to formoterol","volume":"51","author":"Grove","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0194|cit194","first-page":"529s","article-title":"Formoterol: three years therapy in asthma","volume":"6 Suppl 17","author":"Hacki","year":"1993","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF02718117","article-title":"Long term efficacy of formoterol compared with salbutamol","volume":"168 Suppl","author":"Hekking","year":"1990","journal-title":"Lung"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1398-9995.1995.tb01198.x","article-title":"A 4-week comparison of salmeterol and terbutaline in adult asthma","volume":"50","author":"Hermansson","year":"1995","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2281.1998.00110.x","article-title":"Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children","volume":"18","author":"Jartti","year":"1998","journal-title":"Clinical Physiology"},{"issue":"8746","key":"10.1002\/14651858.CD001385.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0140-6736(91)90242-H","article-title":"Exacerbations of asthma in patients on salmeterol","volume":"337","author":"Jenkins","year":"1991","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1378\/chest.109.4.953","article-title":"Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol","volume":"109","author":"Kalra","year":"1996","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1067\/mai.2000.105711","article-title":"Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma - a randomized, double-blind, placebo-controlled trial","volume":"105","author":"Kavuru","year":"2000","journal-title":"Journal of Allergy & Clinical Immunology"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0201|cit201","first-page":"10s","article-title":"Effective salmeterol, salbutamol and placebo in the prevention of exercise induced bronchospasm","volume":"104 Suppl","author":"Kemp","year":"1993","journal-title":"Chest"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1164\/ajrccm.150.6.7952623","article-title":"Prolonged effect of inhaled salmeterol against exercise induced bronchoconstriction after chronic dosing with salmeterol","volume":"150","author":"Kemp","year":"1994","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0091-6749(98)70383-5","article-title":"Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids- Salmeterol Quality of Life Study Group","volume":"101","author":"Kemp","year":"1998","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1164\/ajrccm\/144.3_Pt_1.622","article-title":"A three month comparison of inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma","volume":"144","author":"Kesten","year":"1991","journal-title":"American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0205|cit205","first-page":"415","article-title":"Sustained improvement in asthma with long-term use of formoterol fumarate","volume":"69","author":"Kesten","year":"1992","journal-title":"Annals of Allergy"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0206|cit206","first-page":"465","article-title":"Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma","volume":"1","author":"Kozlik-Feldmann","year":"1996","journal-title":"European Journal of Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1378\/chest.108.1.36","article-title":"Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids","volume":"108","author":"Lai","year":"1995","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1183\/09031936.98.11051081","article-title":"Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo","volume":"11","author":"Langley","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0954-6111(95)90213-9","article-title":"Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma","volume":"89","author":"Langton Hewer","year":"1995","journal-title":"Respiratory Medicine"},{"issue":"12","key":"10.1002\/14651858.CD001385.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/BF01958642","article-title":"Efficacy and safety of salmeterol in childhood asthma","volume":"154","author":"Lenney","year":"1995","journal-title":"European Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0211|cit211","first-page":"155s","article-title":"Influence of salmeterol on eosinophil inflammation in bronchial biopsies from asthmatics on inhaled steroid","volume":"12 Suppl 28","author":"Li","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1164\/ajrccm.160.5.9811052","article-title":"An antiinflammatory effect of salmeterol, a long-acting beta2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma","volume":"160","author":"Li","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9343(98)00086-2","article-title":"Effects of treatment with formoterol on bronchoprotection against methacholine","volume":"104","author":"Lipworth","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0091-6749(99)70530-0","article-title":"A high dose of albuterol does not overcome bronchoprotective sub-sensitivity in asthmatic subjects deceiving regular salmeterol or formoterol","volume":"103","author":"Lipworth","year":"1999","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1378\/chest.117.1.156","article-title":"Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration","volume":"117","author":"Lipworth","year":"2000","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1378\/chest.118.2.321","article-title":"Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous Glycine-16 beta2 adrenoceptor polymorphism","volume":"118","author":"Lipworth","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1398-9995.1992.tb00668.x","article-title":"Twelve months, treatment with inhaled salmeterol in asthmatic patients. effects on b2receptor function and inflammatory cells","volume":"47","author":"Lotvall","year":"1992","journal-title":"Allergy"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/thx.48.2.148","article-title":"Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients","volume":"48","author":"Lundback","year":"1993","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0091-6749(92)90324-U","article-title":"Salmeterol a new inhaled beta2 agonist, has a longer blocking effect than albuterol on hyperventilation induced bronchoconstriction","volume":"89","author":"Malo","year":"1992","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0895-4356(95)00555-2","article-title":"Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients","volume":"49","author":"Mann","year":"1996","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1081-1206(10)62622-1","article-title":"Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma","volume":"83","author":"Martin","year":"1999","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1164\/ajrccm.158.3.9802069","article-title":"Potential masking effects of salmeterol on airway inflammation in asthma","volume":"158","author":"Mcivor","year":"1998","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1164\/ajrccm.152.6.8520751","article-title":"Long term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids","volume":"152","author":"Meijer","year":"1995","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1378\/chest.101.4.1019","article-title":"Formoterol, a new long acting beta2 agonist, inhaled twice daily in stable asthmatic subjects","volume":"101","author":"Midgren","year":"1992","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/rmed.2000.0972","article-title":"Comparison between formoterol 12mcg BID and on-demand salbutamol in moderate persistent asthma","volume":"95","author":"Molimard","year":"2001","journal-title":"Respiratory Medicine"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1164\/ajrccm.159.5.9807128","article-title":"Lack of sub-sensitivity to albuterol after treatment with salmeterol in patients with asthma","volume":"159","author":"Nelson","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0227|cit227","unstructured":"SLGA5020 A single-center, randomized, double-blind, cross-over clinical trial to examine sub-sensitivity in adult subjects with asthma receiving salmeterol xinafoate 42mcg BID and placebo BID www.ctr.gsk.co.uk"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0954-6111(93)90070-G","article-title":"Salmeterol provides prolonged protection against exercise induced bronchoconstriction in a majority of subjects with mild stable asthma","volume":"87","author":"Newnham","year":"1993","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0229|cit229","first-page":"A 210","article-title":"Prolonged attenuation of BHR to methacholine by long acting b2adrenoceptor agonist formoterol","volume":"141","author":"Nichol","year":"1990","journal-title":"American Review of Respiratory Disease"},{"issue":"12","key":"10.1002\/14651858.CD001385.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0954-6111(99)90051-3","article-title":"Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics","volume":"93","author":"Nielsen","year":"1999","journal-title":"Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.121.5.1401","article-title":"Comparison of the effects of salmeterol and formoterol in patients with severe asthma","volume":"121","author":"Nightingale","year":"2002","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.1990.tb03642.x","article-title":"Effect of formoterol, a long-lasting beta2-adrenoceptor agonist, against methacholine-induced bronchoconstriction","volume":"29","author":"Nix","year":"1990","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1440-1843.1999.00153.x","article-title":"Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma","volume":"4","author":"Norhaya","year":"1999","journal-title":"Respirology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/BF02284956","article-title":"Salmeterol protects against hyperventilation induced bronchoconstriction over 12 hours","volume":"43","author":"Nowak","year":"1992","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"8 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1164\/ajrccm.164.8.2104102","article-title":"Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial","volume":"164","author":"O'Byrne","year":"2001","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0954-6111(06)80008-9","article-title":"Inhaled salmeterol in the treatment of patients with moderate to severe ROAD- a 3 month comparison of the efficacy and safety of bd salmeterol (100mcg) and salmeterol (50mcg)","volume":"86","author":"Palmer","year":"1992","journal-title":"Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/rmed.2001.1078","article-title":"Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study","volume":"95","author":"Andersson","year":"2001","journal-title":"Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1183\/09031936.99.14510389","article-title":"Asthma quality of life during 1 year of treatment with budesonide with or without formoterol","volume":"14","author":"Juniper","year":"1999","journal-title":"European Respiratory Journal"},{"issue":"20","key":"10.1002\/14651858.CD001385.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199711133372001","article-title":"Effect of inhaled formoterol and budesonide on exacerbations of asthma","volume":"337","author":"Pauwels","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1164\/ajrccm.160.2.9811100","article-title":"Exacerbations of asthma-a descriptive study of 425 severe exacerbations- The FACET International Study Group","volume":"160","author":"Tattersfield","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1081-1206(10)62606-3","article-title":"Inhaled salmeterol and fluticasone: A study comparing monotherapy and combination therapy in asthma","volume":"82","author":"Pearlman","year":"1999","journal-title":"Annals of Allergy"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1398-9995.1993.tb02410.x","article-title":"The effect of salmeterol on the early and late phase reaction to bronchial allergen and post challenge variation in BHR, blood eosinophils, serum ECP and serum eosinophil protein X","volume":"48","author":"Pedersen","year":"1993","journal-title":"Allergy"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thorax.57.9.791","article-title":"Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose","volume":"57","author":"Price","year":"2002","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0244|cit244","first-page":"446","article-title":"The duration of action of inhaled formoterol dry powder","volume":"50","author":"Quebe-Fehling","year":"1996","journal-title":"British Journal of Clinical Practice"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1436","article-title":"Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma","volume":"147","author":"Rabe","year":"1993","journal-title":"American Review of Respiratory Disease"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1164\/ajrccm\/143.5_Pt_1.998","article-title":"Prolonged protection against methacholine induced bronchoconstriction by the inhaled b2 agonist formoterol","volume":"143","author":"Ramsdale","year":"1991","journal-title":"American Review of Respiratory Disease"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4046\/trd.1997.44.4.815","article-title":"A comparison of salmeterol with salbutamol inhalation in treatment of mild to moderate asthma","volume":"44","author":"Rhee","year":"1997","journal-title":"Tuberculosis and Respiratory Diseases"},{"issue":"27","key":"10.1002\/14651858.CD001385.pub2-BIB0248|cit248","first-page":"3940","article-title":"Salmeterol compared with salbutamol controlled release in patients with moderate bronchial asthma","volume":"158","author":"Ringbaek","year":"1996","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0249|cit249","first-page":"A 210","article-title":"Formoterol, a long acting inhaled b2 agonist, twice daily for 1 year in asthmatic patients","volume":"141","author":"Rosenhall","year":"1990","journal-title":"American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0250|cit250","first-page":"423","article-title":"Salmeterol xinafoate in children on high dose inhaled steroids","volume":"75","author":"Russell","year":"1995","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.95.08060888","article-title":"Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life","volume":"8","author":"Rutten-van","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1081-1206(10)63407-2","article-title":"Efficacy and duration of salmeterol in protecting against exercise induced bronchoconstriction","volume":"76","author":"Schaanning","year":"1996","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pupt.2004.03.003","article-title":"Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma","volume":"17","author":"Schermer","year":"2004","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0011-393X(98)85106-0","article-title":"Does salmeterol facilitate 'step-down' therapy in patients with asthma receiving moderate to high doses of inhaled corticosteroids?","volume":"59","author":"Self","year":"1998","journal-title":"Current Therapeutic Research, Clinical & Experimental"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/ajrccm.161.2.9905091","article-title":"Combined salmeterol 50 mug and fluticasone propionate 250 in the diskus device for the treatment of asthma","volume":"161","author":"Shapiro","year":"2000","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"8754","key":"10.1002\/14651858.CD001385.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/0140-6736(91)93118-S","article-title":"Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms","volume":"337","author":"Shepherd","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/030006059302100203","article-title":"Comparative efficacy of salbutamol and salmeterol in exercise induced asthma","volume":"21","author":"Sichletidis","year":"1993","journal-title":"Journal of International Medical Research"},{"issue":"9-10","key":"10.1002\/14651858.CD001385.pub2-BIB0258|cit258","first-page":"450","article-title":"Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients","volume":"66","author":"Siergiejko","year":"1998","journal-title":"Pneumonologia i Alergologia Polska"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0091-6749(92)90110-N","article-title":"Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma","volume":"90","author":"Simons","year":"1992","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.99.5.655","article-title":"Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics","volume":"99","author":"Simons","year":"1997","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0261|cit261","unstructured":"SLGA2016 www.fda.gov 2001"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0262|cit262","unstructured":"SLGB4011R www.ctr.gsk.co.uk 2005"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0263|cit263","unstructured":"SMO30003 A single-centre, randomised, placebo-controlled, double-blind, 3-way crossover proof-of-concept study to evaluate the effect of reduced fine particle mass (FPM) from the salmeterol 50mg GR106642X metered dose inhaler compared with salmeterol 50mg P11\/12 metered dose inhaler on the peak bronchodilatory effect and bronchoprotection against methacholine-induced bronchoconstriction www.ctr.gsk.co.uk 2005"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0264|cit264","unstructured":"SMS30035 A double-blind, three-way crossover study comparing GR33343G (Salmeterol) 25\u00b5g bd, salmeterol 50\u00b5g bd and placebo in the treatment of childhood asthma. www.ctr.gsk.co.uk 2006"},{"issue":"6877","key":"10.1002\/14651858.CD001385.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/bmj.306.6877.543","article-title":"Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma","volume":"306","author":"Smyth","year":"1993","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0266|cit266","first-page":"325","article-title":"Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu\/g) inhaled twice daily and salbutamol (200 mu\/g) inhaled 4 times daily","volume":"154","author":"Sprogoe-Jakobsen","year":"1992","journal-title":"Ugeskr-Laeger"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0267|cit267","first-page":"36","article-title":"Salmeterol improves control in asthmatic patients treated in general practice. A comparative study of salmeterol and salbutamol in patients with mild to moderate asthma","volume":"157","author":"Staehr","year":"1995","journal-title":"Ugeskrift for Laeger"},{"issue":"49","key":"10.1002\/14651858.CD001385.pub2-BIB0268|cit268","first-page":"7092","article-title":"Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone","volume":"158","author":"Steffensen","year":"1996","journal-title":"Ugeskrift for Laeger"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1164\/ajrccm.156.1.9610113","article-title":"Systemic corticosteroid rapidly reverses bronchodilator sub-sensitivity induced by formoterol in asthmatic patients","volume":"156","author":"Tan","year":"1997","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"9083","key":"10.1002\/14651858.CD001385.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(97)03211-X","article-title":"Association between beta2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics","volume":"350","author":"Tan","year":"1997","journal-title":"Lancet"},{"issue":"9252","key":"10.1002\/14651858.CD001385.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(00)03611-4","article-title":"Comparison of formoterol and terbutaline for as-needed treatment of asthma: as randomised trial","volume":"357","author":"Tattersfield","year":"2001","journal-title":"The Lancet"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0091-6749(92)90325-V","article-title":"A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen induced bronchoconstriction, increase in AR ,increase in urinary leukotriene E4 excretion","volume":"89","author":"Taylor","year":"1992","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1164\/ajrccm.156.6.9703047","article-title":"Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma","volume":"156","author":"Taylor","year":"1997","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0954-6111(98)90309-2","article-title":"Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease","volume":"92","author":"Thomson","year":"1998","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1183\/09031936.98.12030573","article-title":"Tolerability to high doses of formoterol and terbutaline via Turbuhaler(TM) for 3 days in stable asthmatic patients","volume":"12","author":"Totterman","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1155\/1998\/868379","article-title":"Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial","volume":"5","author":"Turner","year":"1998","journal-title":"Canadian Respiratory Journal"},{"issue":"8727","key":"10.1002\/14651858.CD001385.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/0140-6736(90)92894-N","article-title":"Protection against allergen induced asthma by salmeterol","volume":"336","author":"Twentyman","year":"1990","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD001385.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/thx.43.9.674","article-title":"Salmeterol a new long acting inhaled beta agonist: comparison with salbutamol in adult asthmatic patients","volume":"43","author":"Ullman","year":"1988","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1018483310277","article-title":"Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma","volume":"6","author":"Molen","year":"1997","journal-title":"Quality of Life Research"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/thx.52.6.535","article-title":"Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids","volume":"52","author":"Molen","year":"1996","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1183\/09031936.98.12010030","article-title":"Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires","volume":"12","author":"Molen","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0282|cit282","first-page":"529","article-title":"Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists","volume":"56","author":"Woude","year":"2001","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0283|cit283","first-page":"125","article-title":"A multicentre study in general practice to compare the efficacy and tolerability of inhaled salmeterol and terbutaline in the treatment of asthma","volume":"3","author":"Venables","year":"1992","journal-title":"British Journal of Clinical Research"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0284|cit284","first-page":"20","article-title":"A 3 way crossover study comparing twice daily dosing of salmeterol 25mcg and 50mcg with placebo in children with mild to moderate reversible airways disease [abstract]","volume":"143 Suppl 2","author":"Verberne","year":"1991","journal-title":"American Review of Respiratory Disease"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0091-6749(96)80068-6","article-title":"Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma","volume":"97","author":"Verberne","year":"1996","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/ajrccm.156.3.9611067","article-title":"One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group","volume":"156","author":"Verberne","year":"1997","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1164\/ajrccm.158.1.9706048","article-title":"Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma-The Dutch Asthma Study Group","volume":"158","author":"Verberne","year":"1998","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/(SICI)1099-0496(200003)29:3<169::AID-PPUL2>3.0.CO;2-0","article-title":"Long-acting beta2-agonists in childhood asthma: Don't change a winning team (yet)","volume":"29","author":"Verberne","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00044011-199816010-00003","article-title":"Comparison of the bronchodilator effect of inhaled short- and long-acting beta2-agonists in children with bronchial asthma. A randomised trial","volume":"16","author":"Verini","year":"1998","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0954-6111(99)90074-4","article-title":"A comparison of two long acting beta agonists, oral bambuterol and inhaled salmeterol, in the treatment of asthmatics with nocturnal symptoms","volume":"93","author":"Wallaert","year":"1999","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0291|cit291","first-page":"318s","article-title":"Quality of life in long term studies [abstract]","volume":"5","author":"Walters","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/02770909709071202","article-title":"A one-week dose-ranging study of inhaled salmeterol in children with asthma","volume":"34","author":"Weinstein","year":"1997","journal-title":"Journal of Asthma"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1081-1206(10)63068-2","article-title":"Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma","volume":"80","author":"Wenzel","year":"1998","journal-title":"Annals of Allergy"},{"issue":"7092","key":"10.1002\/14651858.CD001385.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/bmj.314.7092.1441","article-title":"The effect of long term treatment with salmeterol on asthma control-a double blind randomised crossover study","volume":"314","author":"Wilding","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0295|cit295","first-page":"52","article-title":"Inhaled salmeterol powder compared with albuterol aerosol given regularly or as needed for asthma","volume":"74","author":"Wolfe","year":"1995","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.97.10020330","article-title":"Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics","volume":"10","author":"Wong","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1164\/ajrccm.153.5.8630590","article-title":"Comparison of the addition of salmeterol to inhaled steroids with the doubling of the dose of inhaled steroids","volume":"153","author":"Woolcock","year":"1996","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1164\/ajrccm.152.4.7551366","article-title":"Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment","volume":"152","author":"Yates","year":"1995","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1164\/ajrccm.156.3.9610051","article-title":"Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma","volume":"156","author":"Yates","year":"1997","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0300|cit300","first-page":"422s","article-title":"24 hour protective effect of salmeterol 50mg v formoterol 24 mg against methacholine induced bronchoconstriction in mild to moderate asthmatic patients: a randomised double blind crossover single dose trial","volume":"7 Suppl 18","author":"Zellweger","year":"1994","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ppul.10404","article-title":"Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma","volume":"37","author":"Zimmerman","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/0091-6749(93)90330-I","article-title":"Inhaled beta2 agonist in asthma","volume":"91","author":"American Academy of Allergy and Clinical Immunology","year":"1993","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1164\/ajrccm.163.1.9910042","article-title":"Are asthma medications and management related to deaths from asthma?","volume":"163","author":"Abramson","year":"2001","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1183\/09031936.96.09010160","article-title":"Interactions of glucocorticoids and beta2 agonists","volume":"9","author":"Adcock","year":"1996","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003495-199754020-00011","article-title":"Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma","volume":"54","author":"Adkins","year":"1997","journal-title":"Drugs"},{"issue":"7382","key":"10.1002\/14651858.CD001385.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Statistics notes: Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003495-199855020-00016","article-title":"Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma","volume":"55","author":"Bartow","year":"1998","journal-title":"Drugs"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD001385.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/S0091-6749(99)70270-8","article-title":"Beta-agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality?","volume":"104","author":"Beasley","year":"1999","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.0.CO;2-P","article-title":"Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature","volume":"29","author":"Bisgaard","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-199447020-00001","article-title":"Long versus short acting beta agonists","volume":"47","author":"Boulet","year":"1994","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0311|cit311","first-page":"186","article-title":"Enhancement of a general quality of life scale: validation of a sleep scale [abstract]","volume":"89","author":"Boyer","year":"1992","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD001385.pub2-BIB0312|cit312","first-page":"S1","article-title":"Guidelines on the management of asthma","volume":"48","author":"British Thoracic Society et al","year":"1993","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0313|cit313","first-page":"S1","article-title":"The British guidelines on asthma management 1995 review and position statement","volume":"52 Suppl 1","author":"British Thoracic Society et al","year":"1997","journal-title":"Thorax"},{"issue":"6880","key":"10.1002\/14651858.CD001385.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bmj.306.6880.776","article-title":"Guidelines for the Management of Asthma: a Summary","volume":"306","author":"British Thoracic Society","year":"1993","journal-title":"British Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD001385.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5694\/j.1326-5377.1976.tb140697.x","article-title":"Mortality from asthma and bronchodilator aerosols","volume":"1","author":"Campbell","year":"1976","journal-title":"Medical Journal of Australia"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0316|cit316","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010005.pub2","article-title":"Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews","author":"Cates","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0317|cit317","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010314.pub2","article-title":"Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews","author":"Cates","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00006842-199311000-00010","article-title":"The development of child centred, disease specific questionnaires for living with asthma","volume":"55","author":"Christie","year":"1993","journal-title":"Psychosomatic Medicine"},{"issue":"8875","key":"10.1002\/14651858.CD001385.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0140-6736(93)92695-P","article-title":"Regular inhaled salbutamol and airway responsiveness to allergen","volume":"342","author":"Cockcroft","year":"1993","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/thx.51.10.1051","article-title":"Functional antagonism produced by inhaled beta agonists","volume":"51","author":"Cockcroft","year":"1996","journal-title":"Thorax"},{"issue":"8644","key":"10.1002\/14651858.CD001385.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(89)92505-1","article-title":"Prescribed fenoterol and death from asthma in New Zealand 1981-1983. A case control study","volume":"1","author":"Crane","year":"1989","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0322|cit322","first-page":"1773","article-title":"Long acting beta agonists. Role in primary care asthma treatment","volume":"43","author":"D'Urzo","year":"1997","journal-title":"Canadian Family Physician"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.108.6.1768","article-title":"Asthma mortality and beta agonists","volume":"108","author":"Skorodin","year":"1995","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1378\/chest.107.4.1116","article-title":"Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?","volume":"107","author":"Devoy","year":"1995","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD001385.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1398-9995.1994.tb00782.x","article-title":"Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies","volume":"49","author":"Faurschou","year":"1994","journal-title":"Allergy"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00435387","article-title":"The reproducibility of the Childhood Asthma Questionnaires: measures of quality of life for children with asthma aged 4-16 yrs","volume":"3","author":"French","year":"1994","journal-title":"Quality of Life Research"},{"issue":"27","key":"10.1002\/14651858.CD001385.pub2-BIB0327|cit327","first-page":"133","article-title":"Safety of salmeterol in the treatment of asthma","volume":"5","author":"Fuller","year":"1995","journal-title":"European Respiratory Review"},{"issue":"5","key":"10.1002\/14651858.CD001385.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1378\/chest.117.5.1319","article-title":"The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction","volume":"117","author":"Giannini","year":"2000","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0329|cit329","volume-title":"Global strategy for asthma management and prevention","author":"National Heart Lung and Blood Institute\/WHO","year":"1995"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1046\/j.1365-2222.2000.00088.x","article-title":"Global initiative for asthma (GINA) and its objectives","volume":"30 Suppl 1","author":"Bousquet","year":"2000","journal-title":"Clinical & Experimental Allergy"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0331|cit331","article-title":"Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma (Cochrane Review)","author":"Greenstone","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0332|cit332","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.200509-1405OC","article-title":"Sequence, Haplotype and Association Analysis of ADR{beta}2 in Multi-Ethnic Asthma Case\/Control Subjects","author":"Hawkins","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD001385.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0954-6111(00)90129-X","article-title":"The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients","volume":"94 Suppl F","author":"Howarth","year":"2000","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0954-6111(06)80163-0","article-title":"The Living with Asthma Questionnaire","volume":"85 Suppl B","author":"Hyland","year":"1991","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised control trials: is blinding really necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1183\/09031936.01.00205801","article-title":"The European community respiratory health survey: what are the main results so far?","volume":"18","author":"Janson","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1513\/pats.200402-010MS","article-title":"Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease","volume":"1","author":"Johnson","year":"2004","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/thx.47.2.76","article-title":"Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials","volume":"47","author":"Juniper","year":"1992","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific quality of life questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1164\/ajrccm.164.6.2010107","article-title":"Long-acting inhaled beta(2)-agonist therapy in asthma","volume":"164","author":"Kips","year":"2001","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/ajrccm\/140.4.917","article-title":"The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial hyperresponsiveness","volume":"140","author":"Lai","year":"1989","journal-title":"American Review of Respiratory Disease"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/cs0960253","article-title":"Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short and long-acting beta2-agonist therapy","volume":"96","author":"Lipworth","year":"1999","journal-title":"Clinical Science"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1378\/chest.115.2.324","article-title":"Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients","volume":"115","author":"Lipworth","year":"1999","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1378\/chest.113.4.1095","article-title":"Long-acting inhaled beta2-agonists in asthma therapy","volume":"113","author":"Moore","year":"1996","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0346|cit346","volume-title":"Asthma management handbook","author":"National Asthma Campaign","year":"2002"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0347|cit347","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005307.pub2","article-title":"Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults","author":"Ni Chroinin","year":"2004","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0348|cit348","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005535","article-title":"Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (Cochrane Review)","author":"Ni Chroinin","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6 Pt 2","key":"10.1002\/14651858.CD001385.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1164\/ajrccm\/147.6_Pt_2.S29","article-title":"An explanation of the asthma paradox","volume":"147","author":"Page","year":"1993","journal-title":"American Review of Respiratory Disease"},{"issue":"11","key":"10.1002\/14651858.CD001385.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1183\/09031936.97.10112489","article-title":"Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency","volume":"10","author":"Palmqvist","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1034\/j.1399-3003.2000.15b01.x","article-title":"Delivering effective asthma care- how do we implement asthma guidelines?","volume":"15","author":"Partridge","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1183\/9031936.00.16337700","article-title":"Comparison of asthma prevalence in the ISAAC and the ECRHS. ISAAC Steering Committee and the European Community Respiratory Health Survey. International Study of Asthma and Allergies in Childhood","volume":"16","author":"Pearce","year":"2000","journal-title":"European Journal of Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1183\/09031936.03.00109702","article-title":"Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo","volume":"21","author":"Reid","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD001385.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7326\/0003-4819-144-12-200606200-00126","article-title":"Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths","volume":"144","author":"Salpeter","year":"2006","journal-title":"Ann Intern Med"},{"issue":"6558","key":"10.1002\/14651858.CD001385.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/bmj.293.6558.1342","article-title":"Asthma mortality: comparison between New Zealand and England","volume":"293","author":"Sears","year":"1986","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001385.pub2-BIB0356|cit356","first-page":"54A","article-title":"Asthma treatment: inhaled beta-agonists","volume":"5 Suppl A","author":"Sears","year":"1998","journal-title":"Canadian Respiratory Journal"},{"issue":"42 Suppl","key":"10.1002\/14651858.CD001385.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1398-9995.1998.tb04888.x","article-title":"The pharmacologic and clinical properties of Oxis (formoterol) Turbuhaler","volume":"53","author":"Selroos","year":"1998","journal-title":"Allergy"},{"issue":"1","key":"10.1002\/14651858.CD001385.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0954-6111(94)90184-8","article-title":"Respiratory arrests in young asthmatics on salmeterol","volume":"88","author":"Shale","year":"1994","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1378\/chest.121.3.1002","article-title":"MIASMA: asthma exacerbation reduction with salmeterol","volume":"121","author":"Shrewsbury","year":"2002","journal-title":"Chest"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD001385.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/ajrccm.159.4.9806052","article-title":"Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group","volume":"159","author":"Sont","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM199202203260801","article-title":"The use of beta-agonists and the risk of death and near death from asthma","volume":"326","author":"Spitzer","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD001385.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00005650-199011000-00006","article-title":"Functional status II(R). A measure of child health status","volume":"28","author":"Stein","year":"1990","journal-title":"Medical Care"},{"issue":"3 Pt 2","key":"10.1002\/14651858.CD001385.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1164\/ajrccm\/154.3_Pt_2.S84","article-title":"National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Program working group report on the cost effectiveness of asthma care","volume":"154","author":"Sullivan","year":"1996","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"26","key":"10.1002\/14651858.CD001385.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/0024-3205(93)90730-Q","article-title":"Clinical pharmacology of long-acting beta-receptor agonists","volume":"52","author":"Tattersfield","year":"1993","journal-title":"Life Sciences"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1164\/ajrccm.156.6.9703047","article-title":"Comparison of salmeterol and albuterol induced bronchoprotection against AMP and histamine in mild asthma","volume":"156","author":"Taylor","year":"1997","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD001385.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/thorax.55.7.595","article-title":"Interactions between corticosteroids and beta agonists","volume":"55","author":"Taylor","year":"2000","journal-title":"Thorax"},{"issue":"11-12","key":"10.1002\/14651858.CD001385.pub2-BIB0367|cit367","first-page":"650","article-title":"Thoracic society of Australia and New Zealand. Asthma management plan","volume":"151","author":"Woolcock A. Rubinfeld AR. Seale JP. Landau LL. Antic R. Mitchell","year":"1989","journal-title":"Medical Journal of Australia"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1018483310277","article-title":"Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma","volume":"6","author":"Molen","year":"1997","journal-title":"Quality of Life Research"},{"issue":"8","key":"10.1002\/14651858.CD001385.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1183\/09031936.96.09081684","article-title":"Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action","volume":"9","author":"Noord","year":"1996","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001385.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1034\/j.1399-3003.2000.15d02.x","article-title":"Do long-acting beta2-adrenergic agonists deserve a different place in guidelines for the treatment of asthma and COPD?","volume":"15","author":"Schayck","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD001385.pub2-BIB0371|cit371","first-page":"156S","article-title":"An overview of nine clinical trials of salmeterol in an asthmatic population","volume":"8","author":"Verberne","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD001385.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0954-6111(98)90385-7","article-title":"A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease","volume":"92","author":"Vervloet","year":"1998","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001385.pub2-BIB0373|cit373","first-page":"209","article-title":"Salmeterol for the treatment of asthma","volume":"75","author":"Weinberger","year":"1995","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001385.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1081-1206(10)62204-1","article-title":"The rising prevalence of asthma in young Melbourne adults is associated with improvement in treatment","volume":"87","author":"Woods","year":"2001","journal-title":"Annals of Allergy, Asthma, & Immunology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001385.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:59:04Z","timestamp":1736783944000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001385.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":374,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001385.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,24]]}}}